GlassScriptPhysician profile
Jordan Ashley Stancombe
NPI 1902214521
$4,575.08
in general payments reported to CMS, 2019-2025
20 companies · $915 in 2025
The $915 reported for 2025 was more than what 82% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $875 · 2022: $1,196 · 2023: $1,144 · 2024: $445 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354 · Education: $99.99 · Consulting Fee: $49.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,354.32 |
| Education | $99.99 |
| Consulting Fee | $49.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,429.13 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $1,351.62 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Amgen INC. | $450.55 | 2021-2025 | Tezspire |
| Genentech USA, INC. | $190.61 | 2021-2024 | Xolair |
| Genzyme Corporation | $173.78 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $157.27 | 2021-2024 | Hyqvia, Takhzyro, Cuvitru |
| Novartis Pharmaceuticals Corporation | $117.75 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $112.21 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $99.99 | 2025 | |
| Ars Pharmaceuticals Operations, INC. | $93.88 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $73.71 | 2021-2025 | Dupixent |
| Adma Biomanufacturing LLC | $67.16 | 2022-2023 | |
| Horizon Therapeutics Plc | $54.42 | 2021-2022 | |
| Pfizer INC. | $43.33 | 2022 | |
| Lilly USA, LLC | $36.20 | 2025 | Ebglyss |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $35.69 | 2023 | |
| Csl Behring | $29.47 | 2025 | Hizentra |
| Alk-Abello, INC | $22.53 | 2021 | |
| Grifols USA, LLC | $20.48 | 2025 | Xembify |
| Abbvie INC. | $15.30 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jordan Stancombe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.